WO1998036061A3 - Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity - Google Patents
Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity Download PDFInfo
- Publication number
- WO1998036061A3 WO1998036061A3 PCT/GB1998/000319 GB9800319W WO9836061A3 WO 1998036061 A3 WO1998036061 A3 WO 1998036061A3 GB 9800319 W GB9800319 W GB 9800319W WO 9836061 A3 WO9836061 A3 WO 9836061A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- interleukin
- scarring
- mediated activity
- inhibiting interleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
The present application relates to the use of agents which inhibit Interleukin-6 receptor mediated activity for the treatment of wounds and/or fibrotic disorders such that fibrosis and/or scarring are reduced or prevented. Preferred agents for use in such treatments include Interleukin-6 neutralising antibodies, Interleukin-6 Receptor antagonists and inhibitors of Interleukin-6 Receptor signal transduction.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62203/98A AU6220398A (en) | 1997-02-13 | 1998-02-13 | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9702944.1 | 1997-02-13 | ||
GBGB9702944.1A GB9702944D0 (en) | 1997-02-13 | 1997-02-13 | Reducing fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998036061A2 WO1998036061A2 (en) | 1998-08-20 |
WO1998036061A3 true WO1998036061A3 (en) | 1998-11-12 |
Family
ID=10807559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/000319 WO1998036061A2 (en) | 1997-02-13 | 1998-02-13 | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6220398A (en) |
GB (1) | GB9702944D0 (en) |
WO (1) | WO1998036061A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8945558B2 (en) | 2005-10-21 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating myocardial infarction comprising administering an IL-6 inhibitor |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9818278D0 (en) * | 1998-08-22 | 1998-10-14 | Smith & Nephew | Compositions |
PT1129190E (en) | 1998-11-13 | 2007-08-08 | Immunex Corp | Human tslp dna and polypeptides |
EP1717316B1 (en) * | 2000-06-30 | 2008-08-13 | ZymoGenetics, Inc. | Allelic variant of the Interferon-like protein ZCYTO21 |
PL371773A1 (en) | 2001-07-23 | 2005-06-27 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
EP1572103A4 (en) * | 2002-11-15 | 2008-02-13 | Centocor Inc | Anti-angiogenic uses of il-6 antagonists |
EP1673396A1 (en) * | 2003-09-22 | 2006-06-28 | BioVation GmbH & Co.KG. | Use of antibodies for reducing the biological effectiveness of il-6 |
US20060171943A1 (en) * | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
CA2625773C (en) | 2005-10-14 | 2015-05-12 | Fukuoka University | Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation |
AR057582A1 (en) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES |
US8771686B2 (en) | 2006-01-27 | 2014-07-08 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody |
CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
AU2007282023B2 (en) | 2006-08-03 | 2012-09-13 | Vaccinex, Inc. | Anti-IL-6 monoclonal antibodies and uses thereof |
US9725514B2 (en) | 2007-01-23 | 2017-08-08 | Shinshu University | Chronic rejection inhibitor |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
TWI528973B (en) | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
WO2011149051A1 (en) | 2010-05-28 | 2011-12-01 | 中外製薬株式会社 | Antitumor t cell response enhancer |
EP2802572B1 (en) | 2012-01-13 | 2018-11-07 | President and Fellows of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
KR20190096390A (en) | 2016-12-16 | 2019-08-19 | 싱가포르 헬스 서비시즈 피티이 엘티디 | IL-11 antibody |
GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils |
CA3070089A1 (en) * | 2017-07-19 | 2019-01-24 | Auckland Uniservices Limited | Cytokine modulation |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
EP3801525A4 (en) | 2018-06-08 | 2022-03-23 | The General Hospital Corporation | Inhibitors of prolyl-trna-synthetase |
MX2021008727A (en) | 2019-01-21 | 2021-11-04 | Singapore Health Serv Pte Ltd | Treatment of hepatotoxicity. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992008474A2 (en) * | 1990-11-20 | 1992-05-29 | The National Heart & Lung Institute | Treatment of lung diseases |
EP0617126A2 (en) * | 1993-02-17 | 1994-09-28 | Ajinomoto Co., Inc. | Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor |
WO1994025036A1 (en) * | 1993-04-30 | 1994-11-10 | Chugai Seiyaku Kabushiki Kaisha | Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor |
WO1996012503A1 (en) * | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remedy for diseases caused by il-6 production |
WO1996018648A1 (en) * | 1994-12-14 | 1996-06-20 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Superagonists and antagonists of h il-6, and 3d modelling method for their selection |
WO1997048728A1 (en) * | 1996-06-20 | 1997-12-24 | Koster, Henk, Wilhelmus | Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity |
-
1997
- 1997-02-13 GB GBGB9702944.1A patent/GB9702944D0/en active Pending
-
1998
- 1998-02-13 AU AU62203/98A patent/AU6220398A/en not_active Abandoned
- 1998-02-13 WO PCT/GB1998/000319 patent/WO1998036061A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992008474A2 (en) * | 1990-11-20 | 1992-05-29 | The National Heart & Lung Institute | Treatment of lung diseases |
EP0617126A2 (en) * | 1993-02-17 | 1994-09-28 | Ajinomoto Co., Inc. | Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor |
WO1994025036A1 (en) * | 1993-04-30 | 1994-11-10 | Chugai Seiyaku Kabushiki Kaisha | Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor |
WO1996012503A1 (en) * | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remedy for diseases caused by il-6 production |
WO1996018648A1 (en) * | 1994-12-14 | 1996-06-20 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Superagonists and antagonists of h il-6, and 3d modelling method for their selection |
WO1997048728A1 (en) * | 1996-06-20 | 1997-12-24 | Koster, Henk, Wilhelmus | Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity |
Non-Patent Citations (2)
Title |
---|
R. SAVINO ET AL.: "Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation.", THE EMBO JOURNAL, vol. 13, no. 6, 15 March 1994 (1994-03-15), Oxford, GB, pages 1357 - 1367, XP000565719 * |
T. TAGA ET AL.: "Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 89, no. 22, November 1992 (1992-11-01), Washinton, DC, USA, pages 10998 - 11001, XP002075302 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8945558B2 (en) | 2005-10-21 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating myocardial infarction comprising administering an IL-6 inhibitor |
Also Published As
Publication number | Publication date |
---|---|
WO1998036061A2 (en) | 1998-08-20 |
AU6220398A (en) | 1998-09-08 |
GB9702944D0 (en) | 1997-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998036061A3 (en) | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity | |
WO2001078702A3 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
EP1059100A3 (en) | Combinations of CRF antagonists and renin-angiotensin system inhibitors | |
WO2003057837A3 (en) | Methods for using anti-muc18 antibodies | |
WO2002022153A3 (en) | Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation | |
EP1425277B8 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
IL142921A0 (en) | USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS | |
WO2001015678A3 (en) | Topical use of kappa opioid agonists to treat otic pain | |
AU6530600A (en) | Use of neurotoxin for treating cardiac muscle disorders | |
WO2003032912A8 (en) | Treatment of cns disorders using cns target modulators | |
AU2604301A (en) | Tnf inhibitors for the treatment of neurological, retinal and muscular disorders | |
WO2002072536A8 (en) | Urea derivatives having vanilloid receptor (vr1) antagonist activity | |
WO2001078703A3 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
WO2003045434A3 (en) | Endothelin antagonists ina method and composition for potentiating an opiate analgesic | |
WO1999029729A3 (en) | Antagonists of neuropilin receptor function and use thereof | |
AU2002361811A1 (en) | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | |
AU1423795A (en) | Treatment of normotensive glaucoma with angiotensin ii antagonists | |
WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
AU5241099A (en) | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis | |
WO1997010824A8 (en) | Use of 5ht1b receptor antagonist for the treatment of vascular disease | |
CA2392804A1 (en) | Combined agents for treatment of glaucoma | |
WO2000002551A3 (en) | Methods and compounds for treating depression | |
WO2002092016A3 (en) | Therapeutic use of rank antagonists | |
AU1028601A (en) | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity | |
WO2002098362A3 (en) | Use of rank antagonists to treat cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998535442 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |